- ￥14900 - 24625
- TargetMol
- 美国
- T60811
- 2025年07月11日
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
零下80~20°C
- 保质期：
Powder: -20°C for 3 years In solvent: -80°C for 2 years
- 英文名：
CXCR4 antagonist 7
- 库存：
10
- 供应商：
TargetMol
- CAS号：
1185451-72-2
- 规格：
50 mg/100 mg/25 mg
| 规格： | 50 mg | 产品价格： | ￥19420.0 |
|---|---|---|---|
| 规格： | 100 mg | 产品价格： | ￥24625.0 |
| 规格： | 25 mg | 产品价格： | ￥14900.0 |
Product Introduction
Bioactivity
英文名:CXCR4 antagonist 7
描述:CXCR4 antagonist 7 (Compound PARA-B) is able to be used in the HIV infection, inflammatory diseases, cancer, and WHIM syndrome research which is a antagonist of CXCR4 (IC 50 = 9.3 nM) [1].
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Hematopoietic Progenitor Cell Collection
Hematopoietic progenitor cells can be mobilized from the bone marrow microenvironment into the peripheral blood following treatment of patients with myeloid cytokines (GCSF, GMCSF, IL3), a CXCR4 antagonist (Plerixafor) and/or following
Combinatorial Stem Cell Mobilization in Animal Models
to perform a bone marrow transplant. Recent studies have shown synergistic mobilization of HPCs when G-CSF pretreatment is combined with acute administration of a CXCR4 antagonist suggesting that combinatorial therapies may have therapeutic potential
, as illustrated by the homodimerization of the CXCR4 receptor and the recruitment of ??arrestin2 to agonist?activated G?protein?coupled receptors. This noninvasive and homogeneous assay provides a robust and sensitive proteomic platform with applications for basic
技术资料暂无技术资料 索取技术资料
